Carisma Therapeutics, Inc. (SESN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CorMedix, Inc.

Invivyd, Inc.

Carisma Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Foghorn Therapeutics, Inc.

Fate Therapeutics, Inc.

Verastem, Inc.

Taysha Gene Therapies, Inc.

Vigil Neuroscience, Inc.

Neoleukin Therapeutics, Inc.

Synlogic, Inc.

Why is Carisma Therapeutics, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -4.12% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -46.94

The company has declared positive results for the last 2 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD -37.34 MM
OPERATING PROFIT(Q) Highest at USD -5.42 MM
PRE-TAX PROFIT(Q) Highest at USD -8.85 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -94.88%, its profits have risen by 37.5%

Falling Participation by Institutional Investors

Institutional investors have decreased their stake by -2.21% over the previous quarter and collectively hold 19.15% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -94.88% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Carisma Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Carisma Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Carisma Therapeutics, Inc.

-94.25%

-0.22

437.41%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

63.74%

EBIT Growth (5y)

-4.12%

EBIT to Interest (avg)

-46.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.17

Sales to Capital Employed (avg)

0.64

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.15%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.22

EV to EBIT

-0.04

EV to EBITDA

-0.04

EV to Capital Employed

-0.05

EV to Sales

0.10

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -37.34 MM

OPERATING PROFIT(Q)

Highest at USD -5.42 MM

PRE-TAX PROFIT(Q)

Highest at USD -8.85 MM

NET PROFIT(Q)

Highest at USD -8.85 MM

-10What is not working for the Company

NET SALES(HY)

At USD 3.73 MM has Grown at -70.39%

RAW MATERIAL COST(Y)

Grown by 101.04% (YoY

CASH AND EQV(HY)

Lowest at USD 9.74 MM

Here's what is working for Carisma Therapeutics, Inc.

Operating Cash Flow

Highest at USD -37.34 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -5.42 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -8.85 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -8.85 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Here's what is not working for Carisma Therapeutics, Inc.

Net Sales

At USD 3.73 MM has Grown at -70.39%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Cash and Eqv

Lowest at USD 9.74 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 101.04% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales